HER2 Targeting in Esophagogastric Cancer: Redefining the Landscape and Breaking Barriers.
J Natl Compr Canc Netw
; 21(4): 423-429, 2023 04.
Article
in En
| MEDLINE
| ID: mdl-37015333
ABSTRACT
HER2 is overexpressed in approximately 20% of esophagogastric cancer (EGC) cases. The addition of the anti-HER2 antibody, trastuzumab, to chemotherapy in 2010 was the first targeted treatment to demonstrate an improvement in survival. The aggressive nature and heterogeneous biology of EGC have posed a particular challenge and resulted in numerous negative trials without a change in standard of care for more than a decade. However, with the incorporation of dual HER2 and PD-1 blockade as well as the advent of a new, potent antibody-drug conjugate, trastuzumab deruxtecan, there have been 2 new FDA approvals for this patient population within the past 2 years. Consequently, the management and landscape of HER2-positive EGC is rapidly changing and increasingly optimistic.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Stomach Neoplasms
/
Esophageal Neoplasms
/
Immunoconjugates
Limits:
Humans
Language:
En
Journal:
J Natl Compr Canc Netw
Journal subject:
NEOPLASIAS
Year:
2023
Document type:
Article